Vaxart Inc (NASDAQ:VXRT) Expected to Post Earnings of -$0.36 Per Share

Share on StockTwits

Equities research analysts predict that Vaxart Inc (NASDAQ:VXRT) will report ($0.36) earnings per share for the current fiscal quarter, Zacks reports. Two analysts have issued estimates for Vaxart’s earnings. The highest EPS estimate is ($0.35) and the lowest is ($0.36). Vaxart posted earnings of ($0.92) per share during the same quarter last year, which suggests a positive year-over-year growth rate of 60.9%. The company is expected to announce its next earnings report on Monday, January 1st.

On average, analysts expect that Vaxart will report full-year earnings of ($1.45) per share for the current year, with EPS estimates ranging from ($1.67) to ($1.23). For the next financial year, analysts forecast that the company will report earnings of ($0.79) per share, with EPS estimates ranging from ($0.97) to ($0.61). Zacks Investment Research’s EPS averages are an average based on a survey of research firms that that provide coverage for Vaxart.

Vaxart (NASDAQ:VXRT) last issued its earnings results on Thursday, August 8th. The biotechnology company reported ($0.39) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.50) by $0.11. Vaxart had a negative net margin of 244.38% and a negative return on equity of 131.05%. The firm had revenue of $0.09 million for the quarter, compared to analysts’ expectations of $1.10 million.

Several equities analysts have weighed in on the stock. Brookline Capital Management assumed coverage on shares of Vaxart in a research report on Thursday, August 15th. They set a “buy” rating and a $6.00 price objective on the stock. HC Wainwright set a $2.00 price objective on shares of Vaxart and gave the stock a “buy” rating in a research report on Wednesday, August 21st. Zacks Investment Research upgraded shares of Vaxart from a “hold” rating to a “buy” rating and set a $0.25 price objective on the stock in a research report on Sunday. Finally, ValuEngine cut shares of Vaxart from a “buy” rating to a “hold” rating in a research report on Friday.

NASDAQ VXRT traded down $0.01 during trading hours on Friday, reaching $0.32. The company’s stock had a trading volume of 88,000 shares, compared to its average volume of 295,981. Vaxart has a 52 week low of $0.25 and a 52 week high of $5.00. The company has a current ratio of 2.29, a quick ratio of 2.29 and a debt-to-equity ratio of 0.09. The stock has a market cap of $5.04 million, a PE ratio of -0.12 and a beta of 0.55. The business has a 50-day simple moving average of $0.41 and a 200 day simple moving average of $0.63.

In related news, insider Wouter Latour bought 166,667 shares of the firm’s stock in a transaction on Monday, September 30th. The stock was bought at an average price of $0.30 per share, with a total value of $50,000.10. Also, major shareholder Armistice Capital Master Fund bought 7,333,333 shares of the firm’s stock in a transaction on Monday, September 30th. The shares were bought at an average cost of $0.29 per share, with a total value of $2,126,666.57. Over the last quarter, insiders have acquired 8,520,000 shares of company stock worth $2,539,907. Corporate insiders own 7.30% of the company’s stock.

An institutional investor recently raised its position in Vaxart stock. Vanguard Group Inc. raised its stake in shares of Vaxart Inc (NASDAQ:VXRT) by 65.4% in the second quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 89,209 shares of the biotechnology company’s stock after buying an additional 35,283 shares during the period. Vanguard Group Inc. owned about 0.57% of Vaxart worth $60,000 as of its most recent SEC filing. Institutional investors own 12.34% of the company’s stock.

Vaxart Company Profile

Vaxart, Inc, a clinical-stage company, engages in the discovery and development of oral recombinant protein vaccines based on its proprietary oral vaccine platform. The company's product pipeline includes tablet vaccines that are designed to protect against norovirus, seasonal influenza, and respiratory syncytial virus.

Further Reading: What is a Futures Contract?

Get a free copy of the Zacks research report on Vaxart (VXRT)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Vaxart Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vaxart and related companies with MarketBeat.com's FREE daily email newsletter.